MEDS · Trxade Health, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.3K | - | $590.0K | - | $10.3K | - | $64.9K | $18.7K | - | - |
| Cost of Revenue | $2.5K | - | $15.4K | - | $9.6K | - | $352.7K | $606.3K | - | - |
| Gross Profit | $53.9K | - | $574.6K | - | $673 | - | $3.9K | ($703) | - | - |
| R&D | $794.0K | - | $169.3K | $843.5K | $574.7K | - | $1.25M | - | - | - |
| SG&A | $1.07M | - | $2.17M | $2.93M | $1.36M | - | $168.6K | $415.4K | $4.70M | - |
| Total Operating Expenses | $3.56M | - | $4.94M | $5.16M | $3.57M | - | $3.50M | $1.49M | $5.50M | - |
| D&A | $454.3K | - | - | - | $500 | - | - | - | $500 | - |
| Operating Income | ($3.51M) | - | ($4.36M) | ($5.16M) | ($3.57M) | - | ($3.50M) | ($1.50M) | ($5.50M) | - |
| Interest Expense | $37.0K | - | $1.80M | $653.5K | $98.5K | - | $217.4K | $4.9K | $98.5K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.40M) | - | ($3.61M) | ($6.72M) | ($3.06M) | - | ($3.18M) | ($1.83M) | $21.25M | - |
| EPS - Basic | ($0.08) | - | ($0.19) | ($0.48) | ($0.33) | - | ($1.34) | ($1.30) | $20.49 | - |
| EPS - Diluted | ($0.08) | - | ($0.19) | ($0.48) | ($0.33) | - | ($1.34) | ($1.30) | $16.77 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.54M | $6.66M | $355.7K | $15.4K | $2.05M | $308.1K | $579.1K | $7.72M | $3.50M | $151.9K |
| Accounts Receivable | $722.5K | $731.3K | $590.0K | - | $3.7K | $11.1K | $10.4K | $13.1K | $6.9K | $821.8K |
| Inventory | $210.9K | $213.4K | $234.5K | - | - | - | $7.9K | $6.4K | $5.4K | $968 |
| Accounts Payable | $1.40M | $1.44M | $3.67M | $3.14M | $3.18M | $2.90M | $2.90M | $726.3K | $953.1K | $2.08M |
| Current Assets | $4.77M | $7.92M | $1.42M | $856.6K | $7.83M | $6.31M | $7.26M | $12.14M | $14.03M | $2.75M |
| Total Assets | $80.66M | $84.18M | $104.83M | $104.29M | $106.36M | $104.85M | $94.26M | $14.85M | $16.74M | $12.53M |
| Current Liabilities | $2.80M | $2.74M | $7.35M | $7.69M | $7.46M | $7.91M | $5.41M | $2.90M | $2.95M | $11.56M |
| Long-term Debt | - | - | $2.00M | $3.58M | $3.09M | $2.90M | - | - | - | - |
| Total Liabilities | $13.84M | $14.06M | $22.16M | $26.43M | $25.20M | $25.78M | $9.13M | $3.06M | $3.12M | $11.99M |
| Stockholders' Equity | $66.82M | $70.12M | $82.67M | $77.86M | $81.16M | $79.07M | $85.13M | $11.79M | $13.62M | $542.4K |
| Retained Earnings | ($83.95M) | ($80.55M) | ($52.43M) | ($48.82M) | ($42.10M) | ($39.04M) | ($31.88M) | ($26.50M) | ($24.67M) | ($33.25M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.92M) | - | - | - | ($2.96M) | - | - | - | ($10.19M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | $27.43M | - |
| Financing Cash Flow | ($200.0K) | - | - | - | $4.70M | - | - | - | ($13.90M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 95.6% | - | 97.4% | - | 6.6% | - | 6.0% | -3.8% | - | - |
| Operating margin | -6230.8% | - | -739.1% | - | -34814.9% | - | -5392.7% | -7998.8% | - | - |
| EBITDA margin | -5424.2% | - | - | - | -34810.1% | - | - | - | - | - |
| Net margin | -6040.4% | - | -611.4% | - | -29869.3% | - | -4908.3% | -9807.5% | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 1409.6% | - | 28.7% | - | 5602.3% | - | 1933.3% | - | - | - |
| SG&A / Revenue | 1908.3% | - | 367.0% | - | 13218.4% | - | 260.0% | 2221.6% | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -4.2% | - | -3.4% | -6.4% | -2.9% | - | -3.4% | -12.4% | 126.9% | - |
| Return on equity | -5.1% | - | -4.4% | -8.6% | -3.8% | - | -3.7% | -15.6% | 156.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.70 | 2.89 | 0.19 | 0.11 | 1.05 | 0.80 | 1.34 | 4.18 | 4.75 | 0.24 |
| Quick ratio | 1.63 | 2.82 | 0.16 | 0.11 | 1.05 | 0.80 | 1.34 | 4.18 | 4.75 | 0.24 |
| Cash ratio | 1.26 | 2.44 | 0.05 | 0.00 | 0.27 | 0.04 | 0.11 | 2.66 | 1.19 | 0.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | 0.02 | 0.05 | 0.04 | 0.04 | - | - | - | - |
| Debt / Assets | - | - | 0.02 | 0.03 | 0.03 | 0.03 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -94.8x | - | -2.4x | -7.9x | -36.3x | - | -16.1x | -302.2x | -55.8x | - |
| Equity multiplier | 1.21 | 1.20 | 1.27 | 1.34 | 1.31 | 1.33 | 1.11 | 1.26 | 1.23 | 23.11 |
| Liabilities / Assets | 0.17 | 0.17 | 0.21 | 0.25 | 0.24 | 0.25 | 0.10 | 0.21 | 0.19 | 0.96 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.01 | - | 0.00 | - | 0.00 | 0.00 | - | - |
| Inventory turnover | 0.01 | - | 0.07 | - | - | - | 44.74 | 94.17 | - | - |
| Days sales outstanding | 4682d | - | 365d | - | 133d | - | 59d | 256d | - | - |
| Days inventory outstanding | 31107d | - | 5548d | - | - | - | 8d | 4d | - | - |
| Days payable outstanding | 207172d | - | 86888d | - | 121277d | - | 3005d | 437d | - | - |
| Cash conversion cycle | -171382d | - | -80975d | - | - | - | -2939d | -178d | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 449.1% | - | 809.7% | - | - | - | -96.8% | -99.2% | - | - |
| Revenue CAGR (3y) | -70.7% | - | -37.4% | - | -85.3% | - | -70.6% | -78.6% | - | - |
| Revenue CAGR (5y) | -55.0% | - | -37.8% | - | -65.8% | - | -40.2% | -53.3% | - | - |
| Gross profit growth (YoY) | 7901.5% | - | 14698.4% | - | - | - | -99.8% | - | - | - |
| Operating income growth (YoY) | 1.7% | - | -24.7% | -244.9% | 35.0% | - | -313.9% | -332.7% | -1482.1% | - |
| Net income growth (YoY) | -11.0% | - | -13.3% | -266.5% | - | - | 9.7% | 7.1% | - | - |
| EPS growth (YoY) | 75.8% | - | 85.8% | 63.1% | - | - | 10.1% | 55.2% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -17.7% | -11.3% | -2.9% | 560.6% | 496.0% | 14479.5% | 636.5% | - | 1978.8% | -28.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$136.6K totalIntegra$136.6K · 100.0%
Geographic
$136.6K totalUS$136.6K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing TRxADE HEALTH against the 5 most active filers in the same SIC group.